Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash & Equivalents (2016 - 2025)

United Therapeutics' Cash & Equivalents history spans 17 years, with the latest figure at $1.6 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 8.25% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $1.6 billion, down 8.25%, while the annual FY2025 figure was $1.6 billion, 8.25% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $1.6 billion at United Therapeutics, up from $1.3 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.9 billion in Q1 2025 and bottomed at $795.2 million in Q2 2022.
  • The 5-year median for Cash & Equivalents is $1.1 billion (2023), against an average of $1.2 billion.
  • The largest annual shift saw Cash & Equivalents dropped 15.6% in 2022 before it skyrocketed 51.81% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $894.8 million in 2021, then rose by 7.42% to $961.2 million in 2022, then grew by 25.65% to $1.2 billion in 2023, then skyrocketed by 40.53% to $1.7 billion in 2024, then decreased by 8.25% to $1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Cash & Equivalents are $1.6 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.6 billion (Q2 2025).